Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Stock Information for Awakn Life Sciences

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Awakn Life Sciences

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Awakn Life Sciences Discusses Filing of Financial Statements
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.